Compare Fortinet Inc (FTNT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Mesoblast Limited — how do they compare? Fortinet Inc trades at $189.83 (market cap $138.88B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Fortinet Inc is far larger — about 76.7× Mesoblast Limited's market cap, and Fortinet Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Mesoblast Limited for 14 Days on average.
| FTNT | MESO | |
|---|---|---|
Market Cap | $138.88B | $1.81B |
Volume | 3,857,161 | 240,620 |
Sector | Technology | Health |
52-Week High | $191.27 | $20.96 |
52-Week Low | $75.23 | $13.19 |
Typical Hold Time | 72 Days | 14 Days |
Enterprise Value | $135.30B | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $189.10, down 1.13% today but remains near recent highs with strong technical momentum. The cybersecurity leader demonstrates robust fundamentals with 28.17% net margins and consistent earnings beats, though valuation ratios appear elevated (P/E 66.88, P/S 18.81). Recent news highlights AI security demand driving platform growth, with the company scheduled to report Q3 2026 results on October 28.
Fortinet presents growth potential through cybersecurity market leadership and AI-driven demand, but faces valuation concerns and competitive pressures. The stock's technical strength and fundamental execution support upside, though high multiples require sustained growth to justify current levels. Key risks include execution missteps and market volatility amid elevated expectations.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
